2 weeks Ago By ABMN Staff
The Manufacturers Life Insurance Company reduced its stake in shares of Moderna, Inc. ( NASDAQ:MRNA – Free Report ) by 16.8% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC).
The institutional investor owned 2,894,995 shares of the company’s stock after selling 583,417 shares during the period. The Manufacturers Life Insurance Company’s holdings in Moderna were worth $343,781,000 at the end of the most recent quarter. Several other hedge funds and other institutional investors also recently modified their holdings of the stock.
Ashton Thomas Private Wealth LLC bought a new position in shares of Moderna during the second quarter worth about $26,000. Family Firm Inc. bought a new position in Moderna during the 2nd quarter worth approximately $33,000.
Cedar Wealth Management LLC lifted its holdings in Moderna by 45.0% during the 1st quarter. Cedar Wealth Management LLC now owns 290 shares of the company’s stock worth $31,000 after buying an additional 90 shares during the last quarter.
Westside Investment Management Inc. acquired a new position in shares of Moderna in the 1st quarter worth approximately $32,000. Finally, Bank & Trust Co bought a new stake in shares of Moderna in the 2nd quarter valued at approximately $36,000.
Institutional investors own 75.33% of the company’s stock. Analyst Upgrades and Downgrades A number of equities analysts have commented on the stock.
Piper Sandler decreased their price objective on shares of Moderna from $157.00 to $115.00 and set an “overweight” rating for the company in a report on Friday, September 13th.
William Blair reaffirmed a “market perform” rating on shares of Moderna in a report on Thursday, June 27th. Deutsche Bank Aktiengesellschaft upgraded shares of Moderna from a “sell” rating to a “hold” rating and dropped their price objective for the stock from $85.00 to $80.
00 in a research note on Wednesday, August 7th. Needham & Company LLC restated a “hold” rating on shares of Moderna in a research note on Friday, September 13th. Finally, Oppenheimer lowered Moderna from an “outperform” rating to a “market perform” rating in a report on Friday, September 13th.
Two research analysts have rated the stock with a sell rating, thirteen have given a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat, Moderna presently has an average rating of “Hold” and a consensus price target of $100.44.
Moderna Price Performance Shares of MRNA opened at $63.93 on Friday. The firm has a market capitalization of $24.
57 billion, a price-to-earnings ratio of -4.08 and a beta of 1.67.
The stock’s fifty day moving average is $85.34 and its 200-day moving average is $109.78.
Moderna, Inc. has a one year low of $62.55 and a one year high of $170.
47. The company has a debt-to-equity ratio of 0.05, a quick ratio of 3.
92 and a current ratio of 4.09. Moderna ( NASDAQ:MRNA – Get Free Report ) last released its quarterly earnings results on Thursday, August 1st.
The company reported ($3.33) EPS for the quarter, topping analysts’ consensus estimates of ($3.47) by $0.
14. The company had revenue of $241.00 million for the quarter, compared to the consensus estimate of $128.
41 million. Moderna had a negative net margin of 116.18% and a negative return on equity of 21.
35%. Moderna’s revenue was down 29.9% on a year-over-year basis.
During the same period in the previous year, the firm earned ($3.62) EPS. Equities analysts anticipate that Moderna, Inc.
will post -9.86 EPS for the current year. Insider Buying and Selling In other news, CFO James M.
Mock sold 689 shares of Moderna stock in a transaction on Monday, July 8th. The stock was sold at an average price of $118.24, for a total transaction of $81,467.
36. Following the transaction, the chief financial officer now directly owns 7,269 shares in the company, valued at approximately $859,486.56.
The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website . In related news, CFO James M. Mock sold 1,321 shares of the business’s stock in a transaction that occurred on Wednesday, August 28th.
The shares were sold at an average price of $79.39, for a total value of $104,874.19.
Following the sale, the chief financial officer now directly owns 8,600 shares in the company, valued at approximately $682,754. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website . Also, CFO James M.
Mock sold 689 shares of the firm’s stock in a transaction that occurred on Monday, July 8th. The stock was sold at an average price of $118.24, for a total transaction of $81,467.
36. Following the sale, the chief financial officer now owns 7,269 shares of the company’s stock, valued at $859,486.56.
The disclosure for this sale can be found here . Insiders have sold a total of 78,158 shares of company stock valued at $9,259,012 over the last quarter. Corporate insiders own 15.
70% of the company’s stock. Moderna Company Profile ( Free Report ) Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.
Further Reading Want to see what other hedge funds are holding MRNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Moderna, Inc. ( NASDAQ:MRNA – Free Report ).
Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter ..
